Internal Control · 2025
In this section9 topics
- Internal Control — Board Opinion1 item
- Adequacy & Appropriateness of the Internal Control System1 item
- Internal Control Deficiencies1 item
- Audit Committee & Auditor Observations2 items
- Opinion on the Head of Internal Audit2 items
- Appointment, Discharge & Transfer of the Head of Internal Audit2 items
- Related Party Transactions1 item
- Counterparties & Transactions3 items
- Policy & Future Trends1 item
Internal Control — Board Opinion
Summary of the Board's Opinion on Internal Control
The Board of Directors has considered the assessment form for the adequacy of the company's internal control system, which has been duly reviewed by the Audit Committee. It is of the opinion that the company's internal control system is adequate and appropriate for the size and nature of the company's business operations, and also complies with relevant laws and regulations, as well as the principles of Good Corporate Governance. Furthermore, the established internal control system is appropriately implemented, covering the 5 main components according to the COSO framework.
Adequacy & Appropriateness of the Internal Control System
Internal Control Framework Used
| Framework | Detail |
|---|---|
| The Committee of Sponsoring Organizations of the Treadway Commission (COSO) | The Company continuously prioritizes the oversight of its internal control system to ensure efficient and effective operations, appropriate resource utilization, secure asset protection, reduced opportunities for errors, damages, leakages, waste, or fraud, as well as to support accurate and reliable accounting and financial reporting systems, and compliance with relevant laws, regulations, and rules, including the principles of Good Corporate Governance. The Board of Directors has assigned the Audit Committee to review the results of the Company's internal control system assessment to ensure that the system is adequate, appropriate for the nature and size of the business, and capable of appropriately accommodating changes and potential risks. The Audit Committee has assigned the Internal Audit Department, an independent unit from management, to assess and review the operations of various departments within the Company according to the annual audit plan, monitor corrective actions, and regularly report results to the Audit Committee. The Company's internal control system assessment is based on the international standard framework, Internal Control – Integrated Framework, by The Committee of Sponsoring Organizations of the Treadway Commission (COSO), covering the following five components: 1) Control Environment The Company promotes an attitude among management and personnel that fosters internal control, upholding integrity, ethics, and responsibility. This includes a clear organizational structure and reporting lines, appropriate definition of roles and responsibilities, and human resource policies and practices that support effective operations. The overall control environment is appropriate and supports the effectiveness of the Company's internal control system, with key practices such as: 1.1 The Company establishes a clear organizational structure and reporting lines, along with written delegation of duties and responsibilities, to ensure that personnel clearly understand their roles, authorities, and responsibilities. 2) Risk Assessment The Board of Directors recognizes the importance of risk management and has therefore appointed a Risk Management Committee to oversee the establishment of policies, guidelines, and the framework for the Company's risk management to be efficient and aligned with organizational goals, with key aspects such as: 2.1 The Company clearly defines organizational objectives, establishes risk measurement criteria and acceptable risk levels (Risk Appetite/Tolerance) covering internal and external factors that may affect the achievement of objectives, and conducts risk analysis and management linked to strategic plans and key activities. 2.2 The Company establishes an enterprise risk management policy, with the Risk Management Committee overseeing and defining the overall risk framework. Relevant committees/working groups are responsible for managing risks within their respective areas according to the defined framework, covering administrative, financial, business, operational, safety, occupational health and environmental risks, and other significant risks related to the Company's business operations. 3) Control Activities The Company establishes written policies, regulations, and operating procedures to ensure that operations achieve management's objectives and help reduce risks from errors or fraud in key processes. Important control activities include: 3.1 Management: Clearly define missions, objectives, and operational plans, communicate them to personnel for understanding, allocate appropriate resources, budgets, and staffing, and establish work processes and monitoring to ensure efficiency, effectiveness, and compliance with relevant laws, regulations, and standards. 3.2 Finance and Accounting: Control cash custody, receipts and disbursements, bank deposits, and petty cash advances according to established regulations, along with maintaining complete, accurate, and consistent accounting records. 3.3 Procurement: Establish regulations and requirements for supplies, clearly define duties and responsibilities, such as approval authority, needs determination, acceptance inspection, and control and storage of supplies. 3.4 Human Resources: Establish an appropriate human resource management system covering recruitment, compensation, job responsibility structures, personnel development, performance evaluation, and communication to support personnel in having suitable competencies for their roles and enhancing organizational efficiency. Overall, the Company has appropriate and sufficient control activities, with control mechanisms established for significant risks. Financial reports and operational performance reports (both financial and non-financial) are regularly reviewed by management, the Audit Committee, and the Board of Directors. Furthermore, performance indicators are utilized for management and evaluation throughout the organization. 4) Information & Communication The Company emphasizes information and communication systems by providing information technology systems and channels for accessing necessary operational information to support effective operations, along with establishing information technology security policies and appropriate and comprehensive internal communication processes, such as Intranet systems, bulletin boards, and Line Staff channels. In addition, the Company has communication processes with stakeholders through appropriate channels, such as investor relations activities, and provides channels for reporting information or tips regarding misconduct or fraud from both internal personnel and external stakeholders, with consideration for the safety and protection of whistleblowers. 5) Monitoring Activities The Company continuously monitors and evaluates internal controls as part of the normal operational processes of management, supervisors, and relevant personnel. Furthermore, evaluations are conducted by the Internal Audit Department according to the annual audit plan, and the Audit Committee regularly reviews the performance of risk management and internal control systems. In cases where issues requiring improvement are identified, the Company establishes appropriate response and corrective action guidelines, and monitors progress to ensure completion within the specified timeframe. Should an event occur that could significantly impact the Company, management will report to the Board of Directors or relevant sub-committees, such as the Audit Committee and the Risk Management Committee, and continuously report on progress and corrective measures. Based on the Audit Committee's review, relying on the assessment results from management and the Internal Audit Department, no material deficiencies were found, and the findings are consistent with the auditor's opinion. The Audit Committee is of the opinion that the Company's internal control system is adequate, appropriate, and effective. |
Internal Control Deficiencies
Number of Deficiencies
| Metric | Current Year | Previous Year | Two Years Ago |
|---|---|---|---|
| Total number of internal control system deficiencies (cases) | 0 | 0 | 0 |
Audit Committee & Auditor Observations
Audit Committee's Opinion Differs from the Board's
No
Auditor Has Observations on Internal Control
No
Opinion on the Head of Internal Audit
Head of Internal Audit
3159
Audit Committee's Opinion on the Head of Internal Audit
The company has established an Internal Audit Office and appointed Mr. Techanat Sriratchadakorn as the Head of Internal Audit. The Audit Committee has considered the qualifications, experience, knowledge, capabilities, and performance of the company's Head of Internal Audit and is of the opinion that the Head of Internal Audit possesses knowledge, capabilities, and experience in internal audit, risk management, and internal control systems suitable for the company's business, and performs duties with independence and transparency. Therefore, he is deemed suitable to continue in the said position.
In 2025, the Head of Internal Audit can effectively perform duties such as preparing an annual internal audit plan, regularly reporting audit results and recommendations to the Audit Committee, preparing an assessment of the adequacy of the internal control system, including risk management and anti-corruption matters, to support the company in having appropriate and adequate internal control systems, risk management, and good corporate governance.
Appointment, Discharge & Transfer of the Head of Internal Audit
Requires Audit Committee Approval
Yes
Description
The Company stipulates that the Audit Committee shall have the authority to consider and approve the appointment, transfer, or termination of employment of the Head of Internal Audit or any other unit responsible for internal audit, in accordance with the regulations of the Stock Exchange of Thailand and relevant standards.
Related Party Transactions
Has Related Party Transactions
Yes
Counterparties & Transactions
Monetary Unit
1000000
Counterparties with Potential Conflicts
| Name | Person / Juristic Person | Type of Business | Nature of Relationship | As of Date (YYYY-MM-DD) |
|---|---|---|---|---|
| Vibharam Hospital Company Limited | Juristic Person | Private Hospital | The associate company is 33.85% owned by the Company and has common directors, namely Mr. Chaisit Viriyamettakul, Mr. Pichit Viriyamettakul, Mr. Sithi Panupattanapong, Mr. Pichaya Somboonsin, and Ms. Ruekkhajee Kanjanapithak. | 2025-12-31T00:00 |
| Vibharam-Pak Kret Hospital Company Limited | Juristic Person | Private Hospital | shares are held by Vibharam Hospital Company Limited ("Associate Company") at 88.46 percent, and has a common director, namely Mr. Pichit Viriyamettakul, Mr. Sithi Panupattanapong, Mr. Pichaya Somboonsin, and Ms. Ruekkhajee Kanjanapithak | 2025-12-31T00:00 |
| Innovation Technology Company Limited | Juristic Person | Engineering Consultant | held by the company, amounting to 14.80 percent, and the company's directors/executives include Mr. Chaisit Viriyamettakul, Mr. Chaisit Kupvivat and Mrs. Sasithorn Norakrai collectively hold shares in Innovation Technology Co., Ltd., amounting to 15.35 percent. | 2025-12-31T00:00 |
| Synphaet Company Limited | Juristic Person | Private Hospital | The company holds 10% of the shares, and the common directors are Mr. Sitti Panupattanapong and Mr. Chaisit Wiriyamettakul. | 2025-12-31T00:00 |
| Chaophya Hospital Public Company Limited | Juristic Person | Private Hospital | The company holds 7.68 percent of shares and has common directors, namely Mr. Chaisit Viriyamettakul, Ms. Bowornphan Ratthaprasert, Mr. Pongpat Pathanavanich, and Mr. Nikom Wairatpanij. | 2025-12-31T00:00 |
| Synphaet Serirak Company Limited | Juristic Person | Private Hospital | 8.20 percent of the shares are held by the company, and it has common directors, namely Mr. Pichit Viriyamettakul, Mr. Chaisit Viriyamettakul, Mr. Sithi Panupatnapong, and Mr. Pichaya Somboonsin. | 2025-12-31T00:00 |
| Song Samphan Company Limited | Juristic Person | Private Hospital | 50 percent of the shares are held by Vibharam Hospital Company Limited ("Associate Company"), and the joint directors are Mr. Chaisit Viriyamettakul and Mr. Sitti Panupattanapong. | 2025-12-31T00:00 |
| Vibharam Hospital - Samut Prakan Company Limited | Juristic Person | Private Hospital | 99.48% of shares are held by Vibhavadi Hospital Company Limited ("Associate Company"), and Mr. Pitchaya Somboonsin serves as a common director. | 2025-12-31T00:00 |
| Vibharam Hospital (Amatanakorn) Company Limited | Juristic Person | Private Hospital | Shares are held by Vibhavadi Hospital Company Limited (“Associate Company”) at 75.11%, and the common directors are Mr. Sithi Panupatnapong and Lieutenant General Prompong Peeraboon. | 2025-12-31T00:00 |
| F&S 79 Company Limited | Juristic Person | Private Hospital | Holding shares in the Company at a proportion of 16.64%. | 2025-12-31T00:00 |
| Bangpo Hospital Company Limited | Juristic Person | Private Hospital | 28.57% of the shares are held by Vibhavadi Hospital Public Company Limited. The company's executives, namely Lieutenant General Prompong Peerapul, Mr. Pichit Viriyamettakul, and Mr. Euachart Kanjanapithak, serve as directors. | 2025-12-31T00:00 |
| Chiangmai Ram Medical Business Public Company Limited | Juristic Person | Private Hospital | As a subsidiary, the company holds an 82.57% stake. | 2025-12-31T00:00 |
| Beauty Design Center Company Limited | Juristic Person | Beauty Care | The company holds a 46.25 percent stake. | 2025-12-31T00:00 |
| V Precision Company Limited | Juristic Person | Health and beauty care, anti-aging | It is a subsidiary; the company holds a 70 percent stake. | 2025-12-31T00:00 |
| Directors, Executives, and Employees | Person | Directors, Executives, and Company Employees | 2025-12-31T00:00 | |
| Fertiva Company Limited | Juristic Person | Operating a fertility treatment center | It is a subsidiary of the company, which holds a 96.67 percent stake. | 2025-12-31T00:00 |
Transactions by Counterparty
| Transactions |
|---|
| 0.0 · Necessity: Company providing medical services from patient referrals for treatment. · Description: Company providing medical services from patient referrals for treatment. · As of yesteryear: 0.14 · Nature of transaction: Medical service fees · Audit committee opinion: Such transactions are in the ordinary course of business and have pricing terms comparable to those with other unrelated counterparties. · As of year before yesteryear: 0.1 · 67.7 · Necessity: The Company holds shares in Vibharam Hospital Company Limited. · Description: The company received dividends from its associate company in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · As of yesteryear: 67.7 · Nature of transaction: Dividends Received · Audit committee opinion: This is an item of a general nature in the ordinary course of business, whereby the company receives dividends from its shareholdings, similar to other shareholders. · As of year before yesteryear: 67.7 |
| 901.86 · Necessity: The company holds an 82.57 percent stake. · Description: The Company received dividends from its subsidiary in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · As of yesteryear: 184.88 · Nature of transaction: Dividends Received · Audit committee opinion: This is a transaction of a general nature in the ordinary course of business, whereby the company receives dividends from its shareholding in a subsidiary, similar to other shareholders. · As of year before yesteryear: 221.85 |
| 1.13 · Necessity: Medical service fees from patient referrals · Description: Service fees and the determination of prices/conditions are in accordance with normal business practices, consistent with the terms set for unrelated individuals or entities. · As of yesteryear: 0.73 · Nature of transaction: Medical Service Fees · Audit committee opinion: It is a transaction conducted in the ordinary course of business, with pricing terms comparable to those with other unrelated parties. · As of year before yesteryear: 1.0 |
| 15.18 · Necessity: Service fees and pricing/conditions are in accordance with normal business practices, consistent with the terms set with unrelated parties or entities. · Description: Hospitals require various engineering specialists to oversee, maintain, and repair essential equipment and tools. · As of yesteryear: 10.57 · Nature of transaction: Maintenance service fees for various engineering systems and medical gas systems · Audit committee opinion: It is a transaction conducted in the ordinary course of business, with pricing terms comparable to those with other unrelated parties. · As of year before yesteryear: 10.56 · 2.27 · Necessity: The company provides financial assistance for business operations and customer base expansion, which necessitates increased capital. · Description: The company provides a long-term loan facility of 65 million Baht at an annual interest rate of 4.90%, and a short-term loan facility of 25 million Baht at an interest rate of 4%. · As of yesteryear: 2.46 · Nature of transaction: Interest · Audit committee opinion: This is financial assistance pursuant to Board of Directors' Resolution No. 2/2560 dated May 15, 2017. · As of year before yesteryear: 2.48 · 0.77 · Necessity: The company has provided medical services to employees of Innovation Technology Co., Ltd. The pricing and terms are at arm's length, consistent with those applied to unrelated parties or entities. · Description: The company has provided medical services to the employees of Innovation Technology Co., Ltd. · As of yesteryear: 0.38 · Nature of transaction: Medical Service Fees · Audit committee opinion: It is a transaction conducted in the ordinary course of business, with pricing terms comparable to those with other unrelated parties. · As of year before yesteryear: 0.64 · 1.26 · Necessity: The company received dividends from its 14.80 percent shareholding. The company received dividends from the investee company in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · Description: The company received dividends from its 14.80 percent shareholding. · As of yesteryear: 1.11 · Nature of transaction: Dividends Received · Audit committee opinion: This is a transaction of a general nature in the ordinary course of business, where the company receives dividends from its shareholdings, similar to other shareholders. · As of year before yesteryear: 0.74 |
| 19.0 · Necessity: The company holds a 7.68% stake and receives dividends from the company in accordance with the resolution of the Annual General Meeting of Shareholders, at the same rate as other shareholders. · Description: The company receives dividends from the company in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · As of yesteryear: 15.85 · Nature of transaction: Dividends Received · Audit committee opinion: This is a transaction of a general nature in the ordinary course of business, where the company receives dividends from its shareholdings, similar to other shareholders. · As of year before yesteryear: 15.85 · 3.29 · Necessity: To maintain financial liquidity and to benefit the company by providing additional funding options, with an interest rate lower than that offered by commercial banks at the time. · Description: Issue 90-day short-term promissory notes at an interest rate of 2.85 percent per annum. · As of yesteryear: 0.0 · Nature of transaction: Interest Expense · Audit committee opinion: This is beneficial for the company as it provides more funding options, with interest rates lower than those of commercial banks at the time. · As of year before yesteryear: 0.0 |
| 46.4 · Necessity: The company holds a 10% stake and receives dividends from the investee company in accordance with the resolution of the Annual General Meeting of Shareholders, at the same rate as other shareholders. · Description: The company receives dividends from the company in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · As of yesteryear: 46.4 · Nature of transaction: Dividends Received · Audit committee opinion: This is a transaction of a general nature in the ordinary course of business, where the company receives dividends from its shareholdings, similar to other shareholders. · As of year before yesteryear: 46.4 |
| 10.0 · Necessity: The company holds a 28.25% stake and receives dividends from the investee company in accordance with the resolution of the Annual General Meeting of Shareholders, at the same rate as other shareholders. · Description: The company receives dividends from the company in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · As of yesteryear: 20.0 · Nature of transaction: Dividends Received · Audit committee opinion: This is a transaction of a general nature in the ordinary course of business, where the company receives dividends from its shareholdings, similar to other shareholders. · As of year before yesteryear: 15.0 · 0.05 · Necessity: Medical expenses from patient referral · Description: Pricing and conditions are determined in accordance with normal business practices, consistent with those applied to unrelated individuals or entities. · As of yesteryear: 0.0 · Nature of transaction: Medical expenses · Audit committee opinion: It is a transaction conducted in the ordinary course of business, with pricing terms comparable to those with other unrelated parties. · As of year before yesteryear: 0.0 |
| 0.25 · Necessity: Patient referrals for treatment are few in number. The pricing and conditions are determined in accordance with normal business practices, consistent with the terms set for unrelated individuals or entities. · Description: Medical service fees from patient referral · As of yesteryear: 0.29 · Nature of transaction: Medical expenses · Audit committee opinion: It is a transaction conducted in the ordinary course of business, with pricing terms comparable to those with other unrelated parties. · As of year before yesteryear: 0.26 · 0.0 · Necessity: The company holds a 46.25% stake and receives dividends from the investee company at the same rate as other shareholders, in accordance with the resolution of the Annual General Meeting of Shareholders. · Description: The company receives dividends from the company in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · As of yesteryear: 6.96 · Nature of transaction: Dividends Received · Audit committee opinion: This is an item of a general nature in the ordinary course of business, whereby the company receives dividends from its shareholdings, similar to other shareholders. · As of year before yesteryear: 0.0 · 25.0 · Necessity: This provides the company with more funding options, at an interest rate lower than the commercial bank lending rate at that time, which was 2.90 percent, and without affecting shareholders' rights. · Description: Contract start: July 22, 2024. Expiration: July 31, 2026 (3 years). · As of yesteryear: 30.0 · Nature of transaction: Loan Agreement · Audit committee opinion: This item is beneficial to the company as it provides additional funding options with an interest rate lower than the commercial bank lending rate at that time, which was 2.90 percent, and does not impact shareholders' rights. · As of year before yesteryear: 0.0 · 0.74 · Necessity: To maintain the company's liquidity, this item is beneficial for the company, as it provides additional funding options at an interest rate lower than the commercial bank lending rates at that time. · Description: Long-term loan agreement at an interest rate of 2.90%, which is lower than that of financial institutions and is unsecured. · As of yesteryear: 0.39 · Nature of transaction: Interest Expense · Audit committee opinion: This item is beneficial to the company as it provides additional funding options with an interest rate lower than the commercial bank lending rate at that time, which was 2.90 percent, and does not impact shareholders' rights. · As of year before yesteryear: 0.0 · 4.44 · Necessity: Office space rental. Pricing and rental conditions are consistent with those for other tenants. · Description: Office space rental duration · As of yesteryear: 0.0 · Nature of transaction: Rent and Services · Audit committee opinion: Office space rental. Pricing and rental conditions are consistent with those for other tenants. · As of year before yesteryear: 0.0 |
| 0.67 · Necessity: This involves patient referrals for treatment, where pricing and conditions are determined according to normal business practices, consistent with the terms set for other unrelated individuals or entities. · Description: Patient referral for treatment · As of yesteryear: 2.26 · Nature of transaction: Medical expenses · Audit committee opinion: It is a transaction conducted in the ordinary course of business, with pricing terms comparable to those with other unrelated parties. · As of year before yesteryear: 0.46 · 7.0 · Necessity: The company holds a 70% stake. It receives dividends from the subsidiary in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · Description: The company receives dividends from the company in accordance with the resolution of the Annual General Meeting of Shareholders at the same rate as other shareholders. · As of yesteryear: 14.0 · Nature of transaction: Dividend · Audit committee opinion: This is an item of a general nature in the ordinary course of business, whereby the company receives dividends from its shareholdings, similar to other shareholders. · As of year before yesteryear: 7.0 · 30.0 · Necessity: As it provides the company with increased funding options, at an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and without affecting shareholders' rights. · Description: Loan agreement and promissory notes, effective from November 1, 2023, to October 31, 2026, with an interest rate of 2.90 percent. The conditions stipulate that the lender may redeem the loan before its maturity date, and the borrower may repay the loan before its maturity date. · As of yesteryear: 30.0 · Nature of transaction: Loan Agreement · Audit committee opinion: This item is beneficial to the company as it provides more financing options with an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and does not affect shareholders' rights. · As of year before yesteryear: 30.0 · 0.87 · Necessity: As it provides the company with increased funding options, at an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and without affecting shareholders' rights. · Description: Loan agreement and promissory notes, effective from November 1, 2023, to October 31, 2026, with an interest rate of 2.90 percent. The conditions stipulate that the lender may redeem the loan before its maturity date, and the borrower may repay the loan before its maturity date. · As of yesteryear: 0.87 · Nature of transaction: Interest Expense · Audit committee opinion: This item is beneficial to the company as it provides more financing options with an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and does not affect shareholders' rights. · As of year before yesteryear: 0.68 · 2.43 · Necessity: Office space rental. Pricing and rental conditions are consistent with those for other tenants. · Description: Rental of company office space · As of yesteryear: 0.0 · Nature of transaction: Rent and Services · Audit committee opinion: Office space rental. Pricing and rental conditions are consistent with those for other tenants. · As of year before yesteryear: 0.0 |
| 456.0 · Necessity: As it provides the company with increased funding options, at an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and without affecting shareholders' rights. · Description: Loan agreement and promissory notes, effective from November 1, 2023, to October 31, 2026, with an interest rate of 2.90 percent. The conditions stipulate that the lender may redeem the loan before its maturity date, and the borrower may repay the loan before its maturity date. · As of yesteryear: 404.0 · Nature of transaction: Loan Agreement · Audit committee opinion: This item is beneficial to the company as it provides more financing options with an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and does not affect shareholders' rights. · As of year before yesteryear: 404.0 · 13.19 · Necessity: As it provides the company with increased funding options, at an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and without affecting shareholders' rights. · Description: Loan agreement and promissory notes, effective from November 1, 2023, to October 31, 2026, with an interest rate of 2.90 percent. The conditions stipulate that the lender may redeem the loan before its maturity date, and the borrower may repay the loan before its maturity date. · As of yesteryear: 16.57 · Nature of transaction: Interest Expense · Audit committee opinion: This item is beneficial to the company as it provides more financing options with an interest rate lower than the commercial bank lending rate at that time, which was 3.25 percent, and does not affect shareholders' rights. · As of year before yesteryear: 16.57 |
| 1.86 · Necessity: Company providing medical services from patient referrals for treatment. · Description: Pricing and conditions are determined in accordance with normal business practice, consistent with those set for unrelated individuals or entities. · As of yesteryear: 0.0 · Nature of transaction: Medical expenses · Audit committee opinion: It is a transaction of a normal commercial nature, with pricing conditions comparable to those of other unrelated counterparties. · As of year before yesteryear: 0.0 |
Policy & Future Trends
Policy, Measures & Approval Process
Policy or Trends for Future Related Party Transactions
The Company has established a policy for related party transactions, both current and future, as follows: For any related party transactions, the Company will set terms and conditions that are fair and consistent with commercial prices and conditions, do not lead to a transfer of benefits, and comply with all relevant laws and regulations. The Company anticipates that related party transactions will continue to occur in the future, such as transactions related to normal commercial operations, including medical services, medical laboratory services, and engineering system maintenance. The Company has appointed the Audit Committee to review and provide opinions on the appropriateness of such transactions, and to consider disclosing information on related party transactions or transactions that may involve conflicts of interest, ensuring accuracy and completeness in accordance with the Securities and Exchange Act, regulations, announcements, orders, or requirements of the Stock Exchange of Thailand, and accounting standards prescribed by the Federation of Accounting Professions of Thailand. In cases where the Audit Committee lacks expertise in considering potential related party transactions, the Company will arrange for individuals with specialized knowledge, such as the Company's auditors or independent experts, to provide opinions on such related party transactions.
Furthermore, for related party transactions that may occur in the future, the Board of Directors must comply with the Securities and Exchange Act, as well as the regulations, announcements, orders, or requirements of the Stock Exchange of Thailand, including compliance with requirements regarding information disclosure, connected transactions, and the acquisition or disposal of the Company's significant assets. The Company shall also arrange for the Audit Committee and the Company's auditors or independent experts (as the case may be) to conduct reviews and provide opinions on the appropriateness of such transactions, and to consider disclosing information on related party transactions or transactions that may involve conflicts of interest, ensuring accuracy and completeness as required by law.
Measures for Investor Protection
The Company has clear stipulations regarding related party transactions and the acquisition or disposal of the Company's significant assets in its Articles of Association, which mandate that directors or individuals who may have a conflict of interest or a potential conflict of interest shall not have the right to vote on such matters. Furthermore, the Company requires the Audit Committee to provide opinions on the necessity and appropriateness of the transactions and to consider disclosing the details of such transactions in the Company's annual report.
In cases where the Audit Committee lacks expertise in considering potential related party transactions, the Company will procure independent experts or the Company's auditors to provide opinions on such related party transactions to assist in the decision-making process of the Board of Directors or the Company's shareholders, as the case may be.

